The Wyden-Grassley US Senate bipartisan Sovaldi Investigation Spotlights a Revenue-Driven Pricing Strategy Behind Gilead’s $1,000 per pill Hepatitis Drug Launch

The US Senate Finance Committee chaired by Senators Ron Wyden, D-Oregon and Chuck Grassley, R-Iowa issued a scathing bipartisan investigative report on December 1, 2015, revealing a clearly intended pricing and marketing strategy undertaken by Gilead Sciences, Inc. with little concern for patient access or availability to its life-saving drug Sovaldi which has a 99% success cure rate for hepatitis C (HCV). The report which took 18 months to complete is amazingly thorough and comprehensive worthy of the US Senate and a Pulitzer Prize for investigative reporting. The full report is available at: A press conference given by Senators […]

HIV and HCV Prescription Drug Co-pay and Patient Assistance Programs

What you need to know to obtain financial assistance for your HIV and HCV medications. I have been working with the Fair Pricing Coalition (FPC) since it was founded by Martin Delaney and Linda Grinberg in 1999. Murray Penner of the National Alliance of State and Territorial AIDS Directors (NASTAD) and I currently serve as co-chairs of the FPC.